CorInnova, Inc.

JLABS @ TMC

2450 Holcombe Blvd. Suite J

Houston, Texas 77021

Phone: (346) 772-0345

Email: info@corinnova.com

© 2018 CorInnova. All Rights Reserved.

FOLLOW US:

  • LinkedIn Social Icon
  • Twitter Social Icon
Please reload

Heart Failure Overview

_____

Heart failure affects more than 26 million people worldwide, including approximately 12 million people in the US and Europe.   In the US, 1 in 5 adults will face heart failure in their lifetime.  There are 960,000 new heart failure cases each year and over 300,000 related deaths annually in the US alone.  Heart failure is the leading cause of hospitalization for age 65+.

 

Heart failure is a chronic, progressive condition in which the heart muscle is unable to pump enough blood to meet the body's needs.  There is no cure for advanced heart failure.  People with heart failure have difficulty breathing, are fatigued, and have difficulty carrying out simple daily activities.

 

Heart failure consists of two types. The first, systolic heart failure, occurs when the heart becomes dilated and unable to pump properly, so the percentage of blood ejected from the heart decreases.  For the most hardy patients, systolic heart failure can be treated with left ventricular assist devices, or LVADs, which increase blood flow. 

 

The second type, Heart Failure with preserved Ejection Fraction (HFpEF) (also called diastolic heart failure) occurs when the left ventricle becomes stiff, does not relax normally, and does not fill properly.  Diastolic blood pressure becomes elevated, increasing pressure inside the left chambers of the heart and the lungs.  HFpEF patients do not have any FDA approved device alternatives.  An estimated 50 to 60% of patients have systolic heart failure and 40 to 50% of patients have HPpEF.

 

 

In animal models of heart failure, CorInnova technology has demonstrated the ability to increase cardiac output, as well as evidence of the ability to enhance filling, showing promise to treat both populations.

None of the statements or information contained on our website is an offer to buy or sell our securities.  Offers to buy or sell our securities are made only pursuant to separate formal legal agreements. Nor should you make any investment decision based on the information on our website, but solely on that information contained in such legal agreements.